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Estimating the returns to United Kingdom
publicly funded musculoskeletal disease
research in terms of net value of improved
health outcomes
Matthew Glover1, Erin Montague2, Alexandra Pollitt2, Susan Guthrie3, Stephen Hanney1, Martin Buxton1
and Jonathan Grant2*
Abstract
Background: Building on an approach applied to cardiovascular and cancer research, we estimated the economic
returns from United Kingdom public- and charitable-funded musculoskeletal disease (MSD) research that arise from
the net value of the improved health outcomes in the United Kingdom.
Methods: To calculate the economic returns from MSD-related research in the United Kingdom, we estimated (1)
the public and charitable expenditure on MSD-related research in the United Kingdom between 1970 and 2013; (2)
the net monetary benefit (NMB), derived from the health benefit in quality adjusted life years (QALYs) valued in
monetary terms (using a base-case value of a QALY of £25,000) minus the cost of delivering that benefit, for a prioritised
list of interventions from 1994 to 2013; (3) the proportion of NMB attributable to United Kingdom research; and (4) the
elapsed time between research funding and health gain. The data collected from these four key elements were used to
estimate the internal rate of return (IRR) from MSD-related research investments on health benefits. We analysed the
uncertainties in the IRR estimate using a one-way sensitivity analysis.
Results: Expressed in 2013 prices, total expenditure on MSD-related research from 1970 to 2013 was £3.5 billion, and for
the period used to estimate the rate of return, 1978-1997, was £1.4 billion. Over the period 1994–2013 the key interventions
analysed produced 871,000 QALYs with a NMB of £16 billion, allowing for the net NHS costs resulting from them and
valuing a QALY at £25,000. The proportion of benefit attributable to United Kingdom research was 30% and the elapsed
time between funding and impact of MSD treatments was 16 years. Our best estimate of the IRR from MSD-related
research was 7%, which is similar to the 9% for CVD and 10% for cancer research.
Conclusions: Our estimate of the IRR from the net health gain to public and charitable funding of MSD-related research
in the United Kingdom is substantial, and justifies the research investments made between 1978 and 1997. We also
demonstrated the applicability of the approach previously used in assessing the returns from cardiovascular and cancer
research. Inevitably, with a study of this kind, there are a number of important assumptions and caveats that we
highlight, and these can inform future research.
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Background
Total global investment in biomedical and health re-
search was estimated at US$240 billion in 2009 [1],
equivalent to approximately US$270 billion in 2016.
These investments are intended to improve health for
patients and the public. But do they? And if so, what are
their returns?
In recent years, researchers and research funders have
aimed to better understand the range of impacts arising
from public and charitable funding for medical research,
including the resulting economic benefits. Such informa-
tion provides accountability to taxpayers and charity
donors, and increases our understanding of how re-
search effectively translates to health gains. In this paper,
we examine the economic returns from musculoskeletal
disease (MSD) research. This is the third in a series of
studies looking at the returns from cardiovascular
(CVD) research [2] and cancer research [3], as well as
the broader economic impacts or spillover effects of re-
search funding [4].
As reviewed by Buxton et al. [5], and updated by
Glover et al. [3] and Raftery et al. [6], the literature that
assesses the value of the benefits of medical research
forms a relatively limited field in terms of methodology
and quality. There are two broad approaches. Firstly, a
‘top down’ approach where overall health gains in a
disease area are related to research investments, but this
requires an estimate of how much of the total health
gain can be attributed to medical research investments.
For example, Funding First [7] argued, in a report enti-
tled ‘Exceptional Returns’, that the steep decline in CVD
deaths in the United States between 1970 and 1990 had
an economic value of US$1.5 trillion annually, and de-
duced that one-third of this (US$500 billion a year)
could be attributed to medical research that led to new
procedures and drugs. The approach was replicated in a
series of studies by Access Economics [8, 9] and Deloitte
Access Economics [10] estimating the return on Austra-
lian biomedical research on the basis of overall improve-
ments in Australian lifespan. The base-case assumption
in these studies was that research was responsible for
50% of the improvements in healthy lifespan, although it
is worth noting that the authors acknowledged there was
no evidence to support this assumed rate of attribution.
The challenge of top-down attribution can be
addressed by examining in a ‘bottom-up’ manner the im-
pacts of specific projects or programmes of research by
tracing forwards from the research to the benefits that
arise. This is the approach developed by HERG [2] and
Glover et al. [3], and adopted in this study. Here, we es-
timate the net monetary benefits (NMB), defined as the
health benefit valued in monetary terms minus the cost
of delivering that health benefit, for a set of key inter-
ventions to reduce MSD that arose from the United
Kingdom application of relevant United Kingdom re-
search. This ‘bottom-up’ approach led to an impressive
but less ‘exceptional’ internal rate of return (IRR) of 9%
and 10% for CVD and cancer research, respectively [2, 3].
However, in both these studies the reduction of smok-
ing over the period analysed had a major impact on the
estimated rate of return. For example, the return on can-
cer research investment declined to 2.4% in a sensitivity
analysis that excluded the effect of smoking cessation,
and attribution of the reduction in smoking to medical
research alone is contestable. Glover et al. [3] therefore
concluded it would be valuable to undertake an investi-
gation in another clinical area, such as MSD, in which
smoking only marginally affects outcome to see whether
similar rates of return are found [3] (smoking has a
comparatively small effect on the musculoskeletal sys-
tem, including a reduction in bone mineral content and
deleterious effects on osteoporosis, fractures and other
MSD [11, 12]). Another prima facie, methodological rea-
son why MSD research is an interesting case to examine
is that it largely relates to chronic conditions, where
health gains occur through improvements in morbidity,
rather than mortality as was the case for CVD and
cancer.
The MSD burden of disease and research
How much biomedical and health research funding is
invested in different disease areas is determined by a
number of factors, including burden of disease, scientific
tractability, donor appeal and previous investment [13].
The United Kingdom Clinical Research Collaboration
[14] report a relatively weak correlation between re-
search investment and burden of disease (using disability
adjusted life years (DALYs)), using the health categories
in the Health Research Classification System (HRCS).1
Whilst ‘cancer’ has the highest proportion of spend and
highest DALY rate (ca. 20%), the combined health
research categories ‘cardiovascular’, ‘blood’ and ‘stroke’,
have approximately 16% of burden, but only 9% of the
spend. ‘Musculoskeletal’ has an even greater skew, with
approximately 9% of the burden but only 3% of spend.
MSD has relatively low rates of mortality, although
evidence indicates incidences of deaths in which MSD
conditions were the underlying cause of death are
under-reported [15, 16]; however, it has a relatively high
prevalence of disability and morbidity. Many musculo-
skeletal conditions are recurrent and lifelong disorders
which can often cause long-term pain, physical disability,
loss of independence, reduced social interaction and a
decline in quality of life [17]. Arthritis conditions, for ex-
ample, are the biggest cause of pain and disability in the
United Kingdom [16].
While most MSD conditions do not require hospital
admission, MSDs are a frequent cause of consultation
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with general practitioners (GP). For example, 15–20%
of all GP consultations involve a patient with MSD
conditions [17]. Further, Woolf et al. [18] found, in a
cross-national comparison, that MSD conditions are
one of the leading causes of both long-term absences
from work and disability pension claims.
MSD conditions affecting joints, bones, muscles and
soft tissues can affect any age group, but the preva-
lence of the disease increases drastically for older
people. The age group most commonly affected (50+
years old) tends to fall predominately outside of the
active labour force. Further, conditions which fall
under MSD affect approximately 10 million people in
the United Kingdom, accounting for £5 billion of the
NHS programme budget spend in England alone [16].
Therefore, MSD has a very different funding and
disease profile to that of the two previous studies on
CVD [2] and cancer [3].
Defining the scope of MSD
For this study, we needed a clear and internationally
defensible definition of ‘musculoskeletal’ disease. Fol-
lowing consultation with a number of experts (see ac-
knowledgements) we used Chapter XIII of the 10th
revision of the International Statistical Classification
of Diseases and Related Health Problems (ICD),
known colloquially as ICD 10 Chapter XIII [19]. One
advantage of using Chapter XIII of ICD 10 is that it
is also the basis of the musculoskeletal category in
the HRCS, meaning that, in many cases, research in-
vestment and health outcomes are defined using the
same criteria.
As discussed in more detail below, we focussed on five
condition groups/areas (with the number indicating the
ICD sub-classification):
 Inflammatory arthritis (M00–M14): particularly
rheumatoid arthritis (RA), juvenile idiopathic
arthritis (JIA), ankylosing spondylitis, psoriatic
arthritis and gout
 Osteoarthritis (M15–M19)
 Connective tissue disorders (M30–M36): particularly
systemic lupus erythematosus (SLE) and
dermatomyositis
 Back pain and dorsopathies (M40–54)
 Osteoporosis (M80–82)
Methods
Overall approach
The overall conceptual approach is summarised in Fig. 1
and requires four key data elements to estimate the IRR
arising from MSD research, namely (1) a time series of
public and charitable funding of MSD-related research;
(2) a time series of NMB of MSD health gains, derived
from the monetised health benefits and healthcare costs
from the actual use of selected interventions; (3) an esti-
mate of the elapsed time between the investment (re-
search funding) and return (health gain) associated with
those interventions; and (4) an estimate of the amount
of health gain that should be attributed to United King-
dom public and charitable research investment in MSD-
related research.
With these four data inputs, the IRR on the public and
charitable investment in MSD research and development
(R&D) can be calculated (it should be noted that the
costs of private sector R&D investments are accounted
for in our analysis as elements within the cost of deliver-
ing healthcare, which are netted off in the NMB). The
costs to the health service of medical interventions pro-
duced by the private sector are assumed to include the
return to the private sector on its R&D investments.
Fig. 1 Overall study approach
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Estimating public and charitable funding of MSD-related
research
We developed a time series of public and charitable fund-
ing of MSD-related research between 1970 and 2013 for
the five largest research funders and a group of other re-
search charities. Each involved a different approach.
Medical Research Council (MRC)
The MRC had previously provided digital copies of its
annual reports dating back to 1911. Between 1976 and
1992, the MRC used a consistent disease classification
system for its research grants, including the category
‘Muscle, Bone and Joints’, which we used for this study.
Data from 1976 to 1992 was extracted from heading 2 of
the annual reports, which classifies projects according to
relevance – that is, the total spend on each project is
placed against any (and all) relevant categories (i.e. it can
be double counted). In comparison, this classification
method is more ‘inclusive’ than the alternative first
heading in the MRC annual reports, which uses a classi-
fication according to the primary purpose, that is, the
total spend equates to the total MRC spend for the year.
As with the previous studies we use this broader defin-
ition of expenditure as it is likely to overstate funding
and thus err on the side of being conservative when cal-
culating the rate of return. In addition, the MRC gave
access to annual reports detailing programme expend-
iture on conditional area ‘Musculoskeletal’ research from
2009 to present day, based on the HRCS definition.
Information was not available between the periods of
1970 to 1975 and 1993 to 2008, in which case we calcu-
lated missing data by inter- and extrapolating the miss-
ing data using various growth functions in Excel.
Wellcome Trust (WT)
The WT produced a detailed list of the grants awarded
from 1970 to present day, and a summary of the total com-
mitment annually. The WT grant management system
identified awards with a 25% or higher proportion classi-
fied as ‘musculoskeletal’, based on the HRCS definition.
Once data was compiled in Excel it was analysed for
patterns and irregularities. For example, in 2008, there
was an increase of approximately £28 million in total
commitment as a result of grants awarded for three
long-term research programmes, all in biomedical engin-
eering. Upon request, WT provided further grant
descriptions on the proportion of grants which had been
classified as less than 50% ‘Musculoskeletal’ to determine
whether the grant was within scope of the disease area
as defined by ICD 10, and we reduced the total commit-
ment to reflect the proportion of the grant falling under
this classification.
To adjust the total commitment data into total ex-
penditure, we assumed an average of 3 years for each
grant and allocated commitment over this time period
and re-calculated expenditure on a per year basis.
Arthritis Research United Kingdom (ARUK)
We assumed all ARUK research expenditure related to
MSD. ARUK provided us with detailed data on the total
commitment as recorded in their income and expend-
iture statements, up to and including 2008, and total ex-
penditure from 2009 onwards.
Once data was collected and collated into an Excel
spreadsheet, it was analysed for irregularities. The data
showed a significant decrease in 2002, which mainly re-
sulted from a change in research strategy, and therefore
a pause in the funding of new grants.
As with the Wellcome Trust we adjusted commitment
data (between 1970 and 2008) by assuming an average
grant length of 3 years and allocating expenditure per
year on that basis.
MSD research activity index
The Department of Health (DH) and Funding Councils
(FCs) did not record information on research funding by
disease area. As with the previous studies, we were able
to generate a total expenditure for both, as described
below, and multiplied this by an ‘activity index’ to esti-
mate the amount of research expenditure on MSD
annually.
The activity index was estimated by looking at the
total expenditure on MSD research by the MRC and the
WT and by comparing it with bibliometric data that was
commissioned to inform other elements of the study.
We also compared it to other sources, including a his-
torical analysis of NHS research, which suggests that
4.5% of research outputs were related to MSD research
[20], and a more recent analysis using the HRCS, which
suggests that 2.8% of research spend by the top 12 pub-
lic funders in the United Kingdom is on MSD research
[14]. Overall, we assumed that 3% of all biomedical and
health research activity is related to MSD research, ran-
ging between 2% and 4% for sensitivity analysis.
Department of Health (DH)
The DH did not have information available on total
MSD research spend, nor did they have data on the total
spend from one source. Additionally, we were interested
in estimating the total research spend by the DH as well
as the National Health Service (NHS), collectively.
Therefore, as with the previous studies, we collected
data from three sources, namely data for 1973 was
entered by hand from Maddock, 1975 [21]; data for
1981 to 1984 was entered by hand from the Annual Re-
view of Government Funded R&D, 1984; and data on
the DH (excluding NHS) from 1986 onwards data were
collected from SET statistical table 3.1 for Department
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of Health and Social Security and the DH. NHS funding
was included from 1995 onwards and subsequent NIHR
data from its founding in 2006.
Data was not available for either NHS or the DH for
1970–1972 or 1974–1980. Further, data for the NHS
could not be extracted prior to 1995. Therefore, we esti-
mated the expected funding in Excel for both NHS and
DH separately to provide a time series for each, and
added the two estimates for the total expenditure. We
then multiplied our total DH/NHS/NIHR funding series
by the activity index (as described above) to generate an
estimate of total DH funding in MSD research.
Funding Councils (FCs)
Similar to the DH, the FCs did not differentiate research
spend by field area, and therefore data on total research
spend was collected and/or estimated and multiplied by
the research activity index (see above). Data was col-
lected from 1989 onwards from three sources, namely
for 1989–1992 from the Research Grant figures for
Great Britain, provided by the HEFCE2; funding from
1993 to 2008 was extracted from the HEFCE main-
stream quality-related research grant allocations for bio-
medical subjects in the years 1993–1994 to 2008–20093;
and funding from 2009 to 2012 was provided through
the HEFCE mainstream quality-related research grant al-
locations for biomedical subjects in the years 2009–2010
to 2012–2013.4
Data could not be extracted from 1970 to 1988; there-
fore, we took a similar approach to that used for DH
funding. We projected the best linear fit of data for the
period 1988 to 2012, then determined the expected
growth from the same time series in order to estimate
for missing annual data.
Other medical research charities
In addition to WT and ARUK, we were aware of other
medical research charities that supported MSD research.
We therefore approached the Association of Medical Re-
search Charities (AMRC), which helped us identify and
select that ‘other group’. Using the HRCS report for
2014 [14], AMRC identified 21 members who funded
MSD research. Two of these charities were out of scope
(because they were funding research outside the United
Kingdom), leaving 19 AMRC members with a total
spend of approximately £18 m per year on MSD re-
search. When WT and ARUK were excluded, the
remaining 17 charities spent approximately £2 m annu-
ally, with the top nine funders of the remaining charities
accounting for 96% of this investment. We therefore
asked these nine other charities for funding data back to
1970. In many cases, the charities did not have suffi-
ciently robust data management systems to go back that
far, and in a number of cases were established at some
point during our time series. Furthermore, some had dif-
ferent financial years and different accounting practices
(i.e. commitment of multiple year research funding vs. in
year expenditure). One charity declined to participate on
the grounds that it did not have the resources to collate
the information. We worked closely with the other char-
ities to develop our best estimated time series and com-
bined this as ‘other medical research charities’ in our
analysis. We deliberately present the aggregate data to
protect the confidentiality of the charities and the data
they provided. Overall the ‘other medical research char-
ities’ account for approximately 4% of total expenditure
on MSD research. For the sensitivity analysis, and to
take into account missing data, we increased the other
expenditure for the ‘other medical research charities’ by
20% for our high estimate.
Taking inflation into account
To calculate the total cumulative spend in real terms,
the total nominal research spend was adjusted for infla-
tion. We applied a Gross Domestic Product deflator
sourced from the HM Treasury (base year = 2013/14)
and adjusted total spend for each year based on this
[22]. Thus, cumulative funding over the period we ex-
amined is expressed in 2013–2014 GBP.
Royalty payments
In principle, any royalty payments received by research
funders as a result of their research investment in the
relevant time period should be netted off in the year
they occur and so reduce the present value of the invest-
ment stream. In previous studies, we had no evidence to
suggest that such royalty payments would be sufficient
to make a substantive difference to the estimated rate of
return. In this case, returns from the royalties relating to
the commercial development of anti-tumour necrosis
factor (anti-TNF) drugs were believed to be sufficient to
have an impact on the IRR. We accessed data from the
published annual accounts of the Kennedy Trust and
data supplied by ARUK to illustrate, in a sensitivity ana-
lysis, the magnitude of the effect of these royalties.
Estimating the NMB from MSD-related research
This element of the study required estimates of the life-
time quality adjusted life years (QALYs) gained and the
net lifetime costs to the NHS of delivering those QALYs
for relevant research-based interventions provided in
each year of the period 1994–2013. Incremental QALYs
encompass both survival and quality of life gains from
an intervention as compared to prior practice. We used
QALYs gained to quantify health gain rather than
changes in DALYs. Although DALYs are used in much
of the literature on overall burden of disease itself to
characterise population health loss, QALYs are the more
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appropriate (and much more commonly used measure,
particularly in the United Kingdom) to characterise the
gain from the use of specific interventions. As far as data
permitted, the methods and sources used were chosen
to provide directly comparable results to those in the
two previous studies on the returns on investment on
CVD and cancer research [2, 3].
Overall estimates of the QALYs, and the costs to the
NHS of delivering them, were built-up by aggregating
estimates for a series of specific interventions. As before,
this approach required identification of the key relevant
MSD interventions and the number of new patients
actually receiving them in the NHS in each year of the
relevant period and estimates of the discounted life-time
QALY gains and net life-time costs per patient resulting
from initiation of the intervention. The aggregated
QALYs gained were then valued in monetary terms
using, as before, a base-case opportunity cost value of a
QALY to the NHS of £25,000 – the midpoint value of
the National Institute for Health and Care Excellence’s
(NICE) threshold range [23]. From this, the similarly ag-
gregated discounted net lifetime NHS costs of delivering
that health benefit were deducted to provide the overall
estimate of the NMB. Any specific circumstances where
data limitations forced deviation from this approach are
noted below.
In the absence of any study that had identified and
quantified the research-based MSD interventions that
had, during the relevant period, contributed most to the
United Kingdom population health gain in this area, or
to substantial changes in costs, we reviewed sources that
might help build an initial view of likely interventions
that might be included. Particularly important in this
stage were studies identifying the burden of MSD dis-
ease in the United Kingdom [24], relevant NICE Path-
ways [25], and NICE and National Collaborative Centre
(NCC) Guidelines [26–29]. With the assistance of
ARUK, we then identified key experts (see Acknowl-
edgements) who, through a workshop (November 2015)
and subsequent direct one-to-one interactions, helped
produce a list of interventions that, in principle, looked
appropriate for inclusion. More detailed review of avail-
able data and cost-effectiveness evidence was undertaken
to confirm the importance of the listed interventions
and to establish whether the necessary estimates of net
costs and benefits, and levels of usage, were available.
Further input from experts was sought (November 2016
to January 2017) to confirm our assumptions, check for
any perceived omissions and to validate the emerging
findings, after which some final adjustments were made.
QALY gains and costs of chosen interventions
We identified appropriate published studies that had esti-
mated the cost-effectiveness of the chosen interventions
in the United Kingdom. Wherever possible, we used inde-
pendent studies produced for NICE or for national clinical
guidelines and published in the Health Technology As-
sessment monograph series, or estimates that had been
reviewed and accepted by NICE. In some instances, evi-
dence was taken directly from NICE Technology
Appraisals or from National Collaborating Centre Guide-
line modelling. Where more than one relevant study had
been undertaken for NICE, we used the most recent to re-
flect the developing evidence base. Where no such study
for NICE was available we sought the most relevant
United Kingdom focussed study from published literature.
Constructing a time series (1994 to 2013) of usage of
MSD interventions
To estimate total NMB for the period, per-patient QALY
gains and net costs for each intervention were multiplied
by the estimated number of new patients who actually
received each intervention in each year. We used the fol-
lowing methods to estimate the time series of usage for
the selected interventions.
Data on the number of patients receiving procedural
interventions (e.g. hip replacements and surgical length
of stay) were gathered from Hospital Episodes Statistics
[30] available for years 1999–2013. For pharmacological
interventions, prescribing data on total annual spend in
the NHS over the period of interest was utilised. Two
primary sources of net ingredient cost (NIC) were avail-
able – (1) Prescription Cost Analysis (PCA) [31] and (2)
Hospital Prescribing England (HPE) [32]. Information
on the average cost of a regimen was used, as well as ac-
counting for usage across different diseases and indica-
tions, to estimate the number of patients receiving the
intervention. Finally, estimates of the average duration
of treatment allowed an estimation of the number of pa-
tients starting treatment in any of the given years of
interest. These data were publically available over differ-
ent time periods (PCA 1998–2013; HPE 2004–2013).
Where an intervention was launched before available
data, but within the time period, a linear interpolation
was performed with usage assumed to be zero the year
before launch. Where an intervention was launched
prior to 1994 the last known value was carried back. For
years where only PCA data were available, but prescrib-
ing also occurred in secondary care, a ratio of the last
year of available PCA and HPE data was used to uprate
years with PCA NIC only. Estimating the number of
patients receiving interventions for low back pain (LBP)
was approached differently, using general practice data
provided for this study from the Clinical Practice Re-
search Datalink (CPRD) [33].
The component figures of numbers of people receiving
treatment interventions were mainly derived from data
for England. To produce a United Kingdom estimate
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(needed because research spend data is for the United
Kingdom) figures were adjusted by a factor reflecting
England’s proportion of the adult United Kingdom
population [34]. All cost estimates were adjusted to
2013–2014 prices using the Hospital and Community
Health Services Pay and Prices Index [35].
The value placed on the estimated QALYs gained is a
critical parameter in estimating the return on research
investment. Given that public spending on health re-
search (whether from taxation or from public donations
to medical charities) can be seen as a decision to achieve
health benefits through research rather than directly
through current healthcare, a value for a QALY (result-
ing from research investment) should arguably reflect
the marginal opportunity cost of generating QALYs in
the NHS. In the calculation of NMB in this study, as in
the previous two studies, we used as the base-case value
an operational opportunity cost value of a QALY in the
middle of the ‘threshold range’, as used by NICE in its
Technology Appraisals of £25,000 [23]. However, this
value can be contested; on the one hand, detailed econo-
metric analysis has estimated that the marginal oppor-
tunity cost value in recent years has been significantly
lower, at approximately £13,000 [36]. On the other, the
value that society places on a QALY as recommended
for use in quantifying the impacts of government pol-
icies is estimated to be £60,000 [37]. In addition to the
base-case, we report values from £13,000 to £60,000.
Analysis of United Kingdom clinical guidelines to estimate
elapsed time and rate of attribution
In the previous studies on CVD [2] and cancer [3] re-
search, the references cited in a sample of clinical guide-
lines were analysed to inform the estimate of the elapsed
time between research spend and net health gain, and
the proportion of net health gain that could be attrib-
uted to United Kingdom research. In the current study
on MSD research, we replicated this approach.
In line with the process for identifying musculoskeletal
interventions, guidelines were identified and classified
in terms of their relevance for inclusion by comparison
to Chapter XIII of the ICD-10 disease classification
[19]. Based on this inclusion criterion, a total of 22 na-
tional guidelines were identified, spanning a range of
practice in the field and issued by ten different bodies
(Table 1).
We used a bespoke computer programme to extract
references from the electronic PDF version of each
guideline. In seven cases, the automated reference ex-
traction failed (because papers were not referenced in a
recognised format). In these instances, references were
extracted manually.
Of the 3640 references cited in the 22 national guide-
lines, 2746 references (75%) were extracted automatically
and 894 (25%) manually. References from non-journal
sources (which were unlikely to constitute original re-
search) and duplicates within the same guideline were
removed, leaving a total of 3237 references. The average
age of the papers cited in a clinical guideline has been
termed the ‘knowledge cycle time’ [38], which is the
average difference between the publication date of the
clinical guideline and the publication date of papers
cited in the guideline. The knowledge cycle time was cal-
culated for the 22 identified national guidelines, and
used to inform the estimated elapsed time.
To estimate the rate of attribution to the United King-
dom, the 3640 extracted references were provided to the
Centre for Science and Technology Studies (CWTS)5 to
be matched to their bibliometric database (which is de-
rived from the Web of Science). Of the extracted refer-
ences, CWTS was able to match 2804 (84%); 40
additional references were manually matched, for a total
of 2844 (85%). Address data was successfully retrieved
from Web of Science for 2762 of these papers. This
dataset was used to estimate the degree of attribution to
the United Kingdom, based on the addresses of all au-
thors of the included papers. These addresses were used
as a proxy for the location in which the research was
conducted, and so it was possible to estimate the pro-
portion of the research cited in guidelines that was con-
ducted in the United Kingdom. The non-matched
references included non-serial outputs, such as books
and websites, journals that are not indexed in the Web
of Science, papers whose publication pre-dates a jour-
nal’s indexation in Web of Science and incorrect
references.
Calculation of the rate of return
Using the four key sources of data summarised in Fig. 1,
we can attribute a proportion of the estimated total an-
nual NMB of the MSD health gain as being due to
United Kingdom research, and relate an equal number
of years of investment to years of NMB, ‘lagged’ by an
estimate of the elapsed time between research and bene-
fit. As in the previous studies, we express this return on
investment as an IRR, which is effectively the discount
rate that would yield a zero net present value. In this ap-
plication, the formula for the IRR is:
−
X20
t¼1
Res Invt
1þ IRRð Þt þ
X20
t¼1þLag
NMBt Attribð Þ
1þ IRRð Þt ¼ 0
Where, Res Inv is the United Kingdom research spend
on MSD in year t, NMB is the net monetary benefit in
year t (monetary value of QALYs gained minus costs of
delivery), Lag is the estimated average years between re-
search spend and health gain, Attrib is the proportion of
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NMB attributed to United Kingdom research and IRR is
the internal rate of return.
The IRR is convenient in enabling a comparison to be
made between non-competing investments of different
sizes with different start dates, as well as providing a dir-
ect comparison with our previous work.
Given the nature of the numerous necessary judgements
involved, the multiple sources of evidence, the multiple
parameters, and the many and various layers of estimates
and assumptions, a probabilistic sensitivity analysis was
not conducted. Even if it were possible, it would not be in-
formative to express all the uncertainty as ranges for each
parameter to reflect stochastic uncertainty in our overall
estimate. Instead, we present a range of one-way
sensitivity analyses that provide an indication of the uncer-
tainty associated with each of the key aggregate parame-
ters that goes into the calculation, namely the size of the
research investment, the average elapsed time between re-
search spend and use of the intervention, the magnitude
of the NMB, the proportion of the NMB that can be
attributed to United Kingdom research, and the effect of
netting-off royalty payments from the investment stream.
Results
Public and charitable funding of United Kingdom MSD-
related research, 1970–2013
Additional file 1 provides a detailed account of the esti-
mated total expenditure by year by organisation over a
Table 1 Summary of United Kingdom guidelines included in analysis of elapsed time and attribution
Provider Guideline Year
British Association/College of
Occupational Therapists
Hand and wrist orthoses for adults with rheumatologic conditions: practice guideline for occupational
therapists
2015
British Association/College of
Occupational Therapists
Occupational therapy for adults undergoing total hip replacement: practice guideline for occupational
therapists
2012
British Pain Society Guidelines for pain management programmes for adults 2013
British Pain Society The assessment of pain in older people 2007
British Society for Rheumatology British Society for Rheumatology and IASP Musculoskeletal Pain Taskforce Guidelines for the integrated
management of musculoskeletal pain symptoms
2008
British Society for Rheumatology British Society for Rheumatology guidelines on standards of care for persons with rheumatoid arthritis 2005
National Institute for Health and Care
Excellence
Osteoarthritis (CG.177) 2014
National Institute for Health and Care
Excellence
Osteoporosis (CG.146) 2012
National Institute for Health and Care
Excellence
Hip fracture (CG.124) 2011
National Institute for Health and Care
Excellence
Rheumatoid arthritis in adults: management (CG.79) 2009
National Institute for Health and Care
Excellence
Low back pain in adults (CG.88) 2009
National Osteoporosis Foundation Clinician’s guide to the prevention and treatment of osteoporosis 2014
National Osteoporosis Guideline
Group
Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men
from the age of 50 years in the United Kingdom
2014
National Osteoporosis Guideline
Group
Osteoporosis: clinical guideline for prevention and treatment: executive summary 2014
National Osteoporosis Society Vitamin D and bone health: a practical clinical guideline for patient management 2013
Royal College of Nursing Administering subcutaneous methotrexate for inflammatory arthritis 2013
Royal College of Physicians Pain: complex regional pain syndrome 2012
Royal College of Physicians Upper limb disorders: occupational aspects of management 2009 2009
Scottish Intercollegiate Guidelines
Network
Management of osteoporosis and the prevention of fragility fractures (CG.142) 2015
Scottish Intercollegiate Guidelines
Network
Management of chronic pain (CG.136) 2013
Scottish Intercollegiate Guidelines
Network
Management of early rheumatoid arthritis (CG.123) 2011
Scottish Intercollegiate Guidelines
Network
Management of hip fracture in older people (CG.111) 2009
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43-year period (1970–2013). A summary of cash
expenditure by funder can be found in Fig. 2. The sig-
nificant spike in 2008 can be attributed to three signifi-
cantly large grants committed by the WT to the
development of large facilities and long-term research
programmes. Figure 3 shows the estimated public and
charitable expenditure on MSD-related research as £1.4
billion from 1978 to 1997 in constant 2013 prices (i.e.
adjusted for inflation). As noted below, 1978–1997 is the
funding period used to calculate the IRR taking into ac-
count the estimated elapsed time. Figure 3 presents a
sensitivity analysis with ‘high’ and ‘low’ scenarios for total
MSD-related research spend, with a range of £1.2 billion
to £1.6 billion.
We additionally obtained two sets of estimates of roy-
alty payments arising from anti-TNF commercialisation
since 2002. The first set was for total royalty payments
to the Kennedy Trust and the second was for the sum of
the royalties retained by the Trust and those remitted to
ARUK. The first is likely to be an over-estimate for our
purposes as it includes some royalties received by private
individuals; the second may underestimate the total sum
that returned into medical research spending. We used
both in the sensitivity analyses.
Interventions
A broad review of the field and discussions with our Ad-
visory Board led us to focus on five main disease areas in
which it appeared that the most significant research-based
changes to healthcare delivery had occurred between 1994
and 2013. These were inflammatory arthritis, osteoarthritis,
connective tissue disorders, osteoporosis and back pain.
Inflammatory arthritis (M00–M09: RA, JIA and
psoriatic arthritis; M10–M12: Gout; M45: Ankylosing
spondylitis)
Key interventions:
• Early, aggressive, combination therapy
• Use of anti-TNFs (infliximab, etanercept, adalimumab, golimumab,
certolizumab)
• Use of other biologics (tocilizumab, abatacept, rituximab)
• Allopurinol and febuxostat in treatment of gout
The management of RA and other associated
inflammatory arthritis has evolved over the studied time
period, predicated by the advent of disease-modifying
anti-rheumatic drugs (DMARDs). Conventional DMARDs
(cDMARDs), most notably methotrexate, are now a stand-
ard component of initial RA management. Treatment has
shifted from monotherapy or slow step-up regimen, to-
wards early and aggressive combination therapy (EACT).
Use of methotrexate served as a proxy for all
conventional DMARD therapy adjusting for a proportion
of methotrexate co-prescribing with biologic DMARDs
(bDMARDs). Methotrexate NIC data was only available
from the PCA, so the estimates of usage may constitute a
slight underestimate. However, given that maintenance
Fig. 2 Cash expenditure on MSD research from 1970 to 2013, by funder
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doses are normally prescribed in primary care and that pa-
tients are likely to receive treatment for 10 years on aver-
age [39], most prescribing will be captured in primary care
prescribing data. Clinical experts estimated that 40% of
patients were managed with EACT in 1994 and essentially
all by 2000.
Since the early 2000s the major new treatment option
of bDMARDs became available for patients with more
severe RA. Anti-TNFs were the initial generation, with
other new bDAMRDs emerging that affect RA through
other mechanisms.
Estimates for the use of both cDMARD and bDMARD
therapy took account of their use in other disease areas
(ulcerative colitis, Crohn’s disease, psoriasis, SLE) and
across inflammatory arthritis indications (where net
health gains are likely to differ). Usage was split
proportional to incidence. NICE estimates were used to
further allocate bDMARD use across different treatment
stages (bDMARD naïve, after failure of an anti-TNF).
Cost effectiveness evidence was available from Tosh et
al. [40] for EACT, and was inferred from Stevenson et al.
[41] for bDMARDs for RA patients not previously
treated with biologics or having failed on cDMARD
therapy. Studies by Malkotti et al. [42], Jackson et al.
[43] and Minton et al. [44] provided estimates of
bDMARD net health gains for patients previously
treated with DMARDs including an anti-TNF.
In the absence of indication specific cost-effectiveness
data for EACT, its benefits were assumed to be the same
for the JIA population and psoriatic arthritis. Shepherd
et al. [45] provided estimates of bDMARD net health
gains after the failure of cDMARD management and
after the failure of an anti-TNF for a JIA population.
Rodgers et al. [46] and Corbett et al. [47] were used for
bDMARD net health gains in psoriatic arthritis and an-
kylosing spondylitis, respectively. Beard et al. [48] pro-
vided cost-effectiveness data on allopurinol and
febuxostat for the treatment of gout.
Osteoarthritis (M15–M19)
Key interventions:
• Move to cementless and hybrid hip prostheses
• Use of minimally invasive hip and knee replacement
• Decreased hospital length of stay for hip and knee replacement from
change in surgical management and early rehabilitation
• Use of Cox-II inhibitors (celcoxib, etoricoxib, meloxicam, etodolac)
• Concomitant Cox-II inhibitor use of proton pump inhibitors
(lansoprazole, omeprazole, esomeprazole pantoprazole)
Joint replacement has constituted a mainstay of
treatment to alleviate pain and regain function of
damaged joints caused by osteoarthritis for some time.
As such, it was not appropriate to include all benefits
Fig. 3 Real term expenditure, 2013 prices, on MSD research 1978 to 1997 (shaded area for 1978 to 1997)
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from hip and knee replacement during the period of
interest. Incremental changes associated with the use of
minimally invasive techniques were, however, relevant to
this period, as well as a trend towards cementless and
hybrid prostheses for hip replacement. There has also
been a marked reduction in hospital length of stay for
patients undergoing joint replacement. Mean hospital
length of stay for hip and knee replacement surgery in
1999 was 12.7 and 12.3 days, respectively. By 2013, these
figures were 5.7 (hip) and 5.1 (knee).
Data from the National Joint Registry [49] was used
alongside Hospital Episodes Statistics to estimate the
number of minimally invasive hip and knee replacements
and type of prostheses used in hip replacement.
Net health gains for cementless and hybrid hip
replacements were taken from Pennington et al. [50] and
minimally invasive joint replacement from de Verteuil et al.
[51]. All hip replacement net health gains were attributed
to osteoarthritis, but include a very small proportion of
replacement due to other reasons such as RA or dysplasia
of the hip. DH reference costs were used to assign a unit
cost to a 1-day reduction in length of stay. Savings were es-
timated by multiplying the annual number of replacements
by the difference in length of stay compared to baseline.
All Cox-II inhibitor use was assumed to be in osteo-
arthritis, with net health gains attributed as such, using
evidence from NCC modelling [52]. Cox-II inhibitors
taken off the market (i.e. Vioxx) were overall assumed to
produce no net benefit. A proportion of concomitant
proton pump inhibitor use was assumed over the period,
starting at 0% in 2006, rising to 30% by 2012 [52].
Connective tissue disorders (M30–M35)
Key interventions:
• Mycophenolate mofetil for SLE
Net health gains resulting from mycophenolate mofetil
were available for treatment of SLE [53], although
limited to a nephritis population.
Osteoporosis (M80–M82)
Key interventions:
• Bisphosphonates (alendronate, etidronate, risedronate, zoledronate)
• Hormonal therapies and dual action bone agents
(raloxifene, teriparatide, denosmuab, strontium ranelate)
Bisphosphonates, the first of which was launched in
the mid-1990s, are recommended as a first-line treat-
ment for post-menopausal osteoporosis and can be used
in both primary and secondary fracture prevention.
Subsequent hormonal therapies have been developed,
which have similar properties.
Some therapies have become generic and these price
changes were reflected in the average cost of a regimen
over time to estimate the number of patients receiving
treatment. However, such changes are not reflected in
the cost-effectiveness evidence, and thus will tend to
overestimate the lifetime costs of delivering healthcare.
Data on zoledronate (Aclasta) NIC was not available in
HPE and the manufacturer provided some internal data.
Stevenson et al. [54] provided estimates of per patient
net health gains for most of these treatments, although
evidence from NICE TA204 2010 [55] was used for
zoledronate and denosumab. These data were provided
split by age group, and as such net health gains were
weighted to reflect the age distribution of the United
Kingdom population. Assumptions about the proportion
of osteoporosis intervention that is aimed at primary
and secondary fracture prevention were taken from
NICE estimates [55, 56].
Back pain (M54)
Key interventions:
• Manual therapy
• Structured exercise programmes
• Combined psychological and physical therapy
The focus was primarily on chronic low back pain and
sciatica as defined by NICE guidance [57]. In the
absence of a comprehensive source through which to
ascertain the number of physical and psychological
interventions for LBP that patients have received over
the period of interest, we had to use a different
approach to estimating the population.
Data on new diagnoses of LBP were obtained from the
CPRD, which provides observational data from United
Kingdom GP practices. Of the Read codes used to
identify relevant LBP, approximately 95% of events were
one of the following: LBP, back pain without radiation
not otherwise specified, sciatica, complaint of LBP, pain
in lumbar spine, mechanical low back pain, chronic low
back pain, back pain, unspecified, or lumbago. Incidence
was defined as the number of incident events divided by
the total registered CPRD population (person years)
after removing participants who had ever had previous
back pain as well as the first year of CPRD sample
follow-up, who were defined as not ‘at risk’.
Incidence was split into sex-specific 5-year age bands.
United Kingdom population figures were used to esti-
mate a total number of incident cases of back pain dur-
ing the period based on the CPRD sample. The focus
was on a chronic population who receive active
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interventions over and above self-management and so
an assumption around the proportion of incidence that
would be chronic in nature was required (40%). Based
on NICE guidance [58], Leeds MSK service (personal
communication) and a CSAG Report [59] we estimated
what proportion of a chronic population would have re-
ceived each of the three identified interventions over the
period of interest. For structured exercise programmes
the proportion was estimated to be 5% in 1994 and 20%
by 2013; for manual therapy, these figures were 3% and
20%, and for combined physical and psychological ther-
apy 0.3% and 2.5%, respectively.
Data on per patient net health gains were taken from
NICE/NCCPC guidelines [58], except for manual
therapy, which was taken from a cost-effectiveness ana-
lysis of the United Kingdom BEAM trial [60].
Net monetary benefit (NMB)
Table 2 shows the contribution to the total estimates of
lifetime QALYs gained from the nine areas addressed, by
year, based on the estimated number of new patients in
which the intervention was initiated (procedural
interventions are delivered in that year only, but
pharmacological treatment duration varies across
interventions). By far the largest contribution to the total
health gain came from improved treatment of RA (40.1%
of the total). Inflammatory arthritis as a whole accounts for
57.5% of the total. Osteoarthritis and osteoporosis are the
next biggest areas (21.7% and 12.2%, respectively).
Table 3 shows the lifetime net costs to the NHS of
new patients initiated on the treatments in question for
each of these areas over the 20-year period. Again, by far
the biggest costs are associated with RA alone or inflam-
matory arthritis taken as a whole. It is notable that
developments for osteoarthritis have led to a substantial
cost saving as a result of lower surgical hospital stay
observed over the period. Less substantial, but signifi-
cant cost savings also arose from treatment of connect-
ive tissue disorders, as a result of avoiding the costs
associated with renal failure in patients with SLE. The
table also reflects that the treatments for LBP that were
adopted were relatively cheap and highly cost-effective.
Table 4 summarises the NMB when the QALYs have
been valued at the base-case value of £25,000 and the
net costs to the NHS of the intervention and its long-
term sequelae have been deducted. At this value of a
Table 2 QALYs gained from key musculoskeletal disease interventions, 1994–2013
Rheumatoid
arthritis
(M00–06)
Psoriatic
arthritis
(M07)
Juvenile
idiopathic
arthritis
(M08–09)
Gout
(M10–12)
Osteoarthritis
(M15–19)
Connective
tissue disorders
(M30–35)
Ankylosing
spondylitis
(M45)
Low back
pain
(M54.5)
Osteoporosis
(M80–82)
Total
QALYs
1994 698 67 205 1009 1944 6 0 534 0 4464
1995 1181 113 346 1015 2135 7 0 619 287 5703
1996 1786 171 523 1021 2825 8 0 882 287 7504
1997 2513 241 736 1027 3520 10 0 1171 458 9675
1998 3363 322 986 1033 4219 11 0 1468 572 11,973
1999 4964 499 1270 1038 4736 19 33 1624 853 15,036
2000 6449 641 1705 1089 5249 29 33 1847 915 17,957
2001 8459 845 2288 1128 7010 46 51 2070 1749 23,644
2002 9657 956 2641 1183 9500 63 46 2267 2400 28,713
2003 11,409 1137 3146 1245 11,737 85 69 2499 3663 34,990
2004 14,474 1457 4090 1309 14,454 109 197 2795 5022 43,907
2005 13,976 1454 4053 1157 11,504 106 212 2765 5974 41,201
2006 17,450 1361 3769 1135 11,652 129 154 2747 6833 45,229
2007 19,551 1858 5321 1260 12,929 156 367 2786 7921 52,149
2008 23,730 2381 6309 1493 13,386 181 392 4288 8955 61,116
2009 28,588 2662 7756 1471 13,383 195 482 5741 10,252 70,529
2010 33,882 3071 8945 1592 14,451 219 577 6999 11,994 81,729
2011 45,401 4007 11,994 1797 14,625 169 708 8546 12,538 99,786
2012 51,586 4453 13,422 1885 14,726 125 809 8385 13,111 108,502
2013 50,407 4813 13,248 2143 15,153 128 853 8212 12,875 107,834
Total 349,523 32,507 92,753 26,032 189,136 1801 4983 68,245 106,660 871,693
Value £8738 m £813 m £2,319 m £651 m £4728 m £45 m £125 m £1706 m £2667 m £21,791 m
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QALY, all areas except treatments for ankylosing spon-
dylitis show a positive NMB. Osteoarthritis is the single
area with the largest NMB (approximately 43.7% of the
total), although inflammatory arthritis as a whole ac-
counts for a similar proportion. Within that total, how-
ever, RA accounts for 28.5%. It contributes to NMB to a
lesser extent than to QALYs because the new DMARDs
have generally been priced to be just acceptable to NICE
at the upper end of its £20,000–30,000 ‘threshold’. In-
deed, the new DMARDs for RA as a whole produced a
negative NMB, but this was offset by large net health
gains from the shift towards early, aggressive combin-
ation therapy. The overall annual figures for monetised
QALYs, net cost of delivery and NMB of key MSD inter-
ventions 1994–2013 are shown Fig. 4. Additional file 2
provides details of the breakdown of estimated numbers
of patients for each intervention in each year and the re-
lated QALY estimates.
Estimating the elapsed time
Our estimate of the elapsed time between research
funding and health gain was based primarily on analysis
of the references cited on clinical guidelines. As
illustrated in Fig. 5, the mean age of the 3237 cited
papers extracted from the 22 guidelines was 9 years. The
median age was 7 years, with an interquartile range of 7
(4–11) years. To produce an estimate of the total
elapsed time between investment and return, as required
for this study, we added on to this value estimates for
(1) the time between the awarding of funding and
publication, and (2) the time between recommendation
and realisation of health gain in clinical practice. Using
the same approach as in our previous studies, we
estimated these two periods to total approximately 7 years
(3 years for the period between funding and publication
and 4 years between recommendation and health gain).
This gave a best estimated elapsed time between spending
on research and health gain of 16 years. We looked at
alternative approaches to estimate the knowledge cycle
time, such as only including the NICE and Scottish
Intercollegiate Guideline Network guidelines (mean
9 years, median 7 years) and looking at only the main
osteoarthritis and RA guidelines, which are the conditions
from which the largest health improvements stem (mean
10 years, median 9 years) Additional file 3 provides details
of the guideline analysis.
Table 3 Net costs of delivery of key musculoskeletal disease interventions, 1994–2013
Rheumatoid
arthritis
(M00–06)
Psoriatic arthritis
(M07)
Juvenile
idiopathic
arthritis
(M08–09)
Gout
(M10–12)
Osteoarthritis
(M15–19)
Connective
tissue disorders
(M30–35)
Ankylosing
spondylitis
(M45)
Low back
pain
(M54.5)
Osteoporosis
(M80–82)
Total net
costs of
delivery
1994 £2.0 m £0.2 m £0.6 m £3.3 m £3.6 m –£0.3 m £0.0 m £5.1 m £0.0 m £14.4 m
1995 £3.3 m £0.3 m £1.0 m £3.3 m £4.2 m –£0.4 m £0.0 m £6.0 m £4.1 m £21.9 m
1996 £5.0 m £0.5 m £1.5 m £3.3 m £10.3 m –£0.4 m £0.0 m £8.5 m £4.1 m £32.8 m
1997 £7.0 m £0.7 m £2.1 m £3.3 m £16.4 m –£0.5 m £0.0 m £11.3 m £14.0 m £54.3 m
1998 £9.4 m £0.9 m £2.8 m £3.4 m £22.5 m –£0.6 m £0.0 m £14.2 m £16.0 m £68.4 m
1999 £33.8 m £3.6 m £3.6 m £3.4 m £26.5 m –£1.0 m £1.3 m £15.7 m £20.4 m £107.4 m
2000 £38.0 m £4.0 m £4.8 m £3.6 m £13.6 m –£1.4 m £1.3 m £17.8 m £21.3 m £103.0 m
2001 £53.7 m £5.5 m £8.9 m £3.7 m £9.1 m –£2.3 m £1.7 m £20.0 m £36.3 m £136.6 m
2002 £53.9 m £5.5 m £9.1 m £3.9 m –£7.7 m –£3.1 m £1.6 m £21.9 m £44.2 m £129.3 m
2003 £71.5 m £7.2 m £13.7 m £4.1 m –£36.0 m –£4.2 m £2.1 m £24.2 m £64.3 m £146.8 m
2004 £150.6 m £13.4 m £38.0 m £4.3 m –£47.7 m –£5.4 m £5.1 m £27.0 m £87.5 m £272.8 m
2005 £158.4 m £15.2 m £44.9 m £3.8 m –£117.8 m –£5.3 m £5.5 m £26.8 m £108.5 m £239.9 m
2006 £211.6 m £11.0 m £26.2 m £3.7 m –£155.2 m –£6.4 m £4.5 m £26.6 m £122.7 m £244.7 m
2007 £275.9 m £21.1 m £67.8 m £4.1 m –£205.5 m –£7.7 m £9.3 m £27.0 m £140.4 m £332.4 m
2008 £308.4 m £27.0 m £69.4 m £4.9 m –£234.4 m –£9.0 m £10.2 m £39.9 m £157.8 m £374.3 m
2009 £376.8 m £27.4 m £90.4 m £4.8 m –£244.1 m –£9.7 m £12.5 m £52.3 m £176.8 m £487.3 m
2010 £456.5 m £31.3 m £102.9 m £5.3 m –£283.0 m –£10.9 m £14.9 m £63.0 m £202.0 m £582.0 m
2011 £594.1 m £37.7 m £133.5 m £6.0 m –£331.7 m –£8.4 m £17.9 m £76.3 m £211.7 m £737.2 m
2012 £684.2 m £41.0 m £148.2 m £6.3 m –£343.8 m –£6.2 m £20.3 m £74.8 m £220.9 m £845.6 m
2013 £683.9 m £53.8 m £154.3 m £7.3 m –£367.6 m –£6.4 m £21.6 m £73.3 m £215.8 m £836.0 m
Total £4178.2 m £307.3 m £923.5 m £85.6 m –£2268.3 m –£89.4 m £129.9 m £631.5 m £1868.9 m £5767.2 m
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Table 4 Net monetary benefit from key musculoskeletal disease interventions, 1994–2013
Rheumatoid
arthritis
(M00–06)
Psoriatic
arthritis
(M07)
Juvenile
idiopathic
arthritis
(M08–09)
Gout
(M10–12)
Osteoarthritis
(M15–19)
Connective
tissue disorders
(M30–35)
Ankylosing
spondylitis
(M45)
Low back
pain
(M54.5)
Osteoporosis
(M80–82)
Total net
monetary
benefit
1994 £15.5 m £1.5 m £4.5 m £21.9 m £45.0 m £0.4 m £0.0 m £8.2 m £0.0 m £97.2 m
1995 £26.2 m £2.5 m £7.7 m £22.1 m £49.1 m £0.5 m £0.0 m £9.5 m £3.0 m £120.7 m
1996 £39.6 m £3.8 m £11.6 m £22.2 m £60.3 m £0.6 m £0.0 m £13.6 m £3.0 m £154.8 m
1997 £55.8 m £5.3 m £16.4 m £22.3 m £71.6 m £0.7 m £0.0 m £18.0 m -£2.6 m £187.6 m
1998 £74.7 m £7.1 m £21.9 m £22.4 m £83.0 m £0.8 m £0.0 m £22.5 m -£1.6 m £230.9 m
1999 £90.3 m £8.8 m £28.2 m £22.6 m £91.9 m £1.4 m –£0.5 m £24.9 m £0.9 m £268.5 m
2000 £123.2 m £12.0 m £37.9 m £23.7 m £117.6 m £2.1 m –£0.5 m £28.3 m £1.6 m £345.9 m
2001 £157.8 m £15.6 m £48.3 m £24.5 m £166.2 m £3.4 m –£0.5 m £31.7 m £7.5 m £454.5 m
2002 £187.5 m £18.4 m £56.9 m £25.7 m £245.2 m £4.7 m –£0.5 m £34.8 m £15.8 m £588.5 m
2003 £213.7 m £21.3 m £65.0 m £27.1 m £329.4 m £6.3 m –£0.4 m £38.3 m £27.3 m £728.0 m
2004 £211.2 m £23.0 m £64.3 m £28.5 m £409.1 m £8.1 m –£0.2 m £42.8 m £38.0 m £824.9 m
2005 £191.0 m £21.1 m £56.4 m £25.1 m £405.4 m £7.9 m –£0.2 m £42.4 m £40.9 m £790.1 m
2006 £224.6 m £23.1 m £68.0 m £24.7 m £446.5 m £9.7 m –£0.6 m £42.1 m £48.1 m £886.1 m
2007 £212.8 m £25.4 m £65.2 m £27.4 m £528.7 m £11.6 m –£0.2 m £42.7 m £57.6 m £971.3 m
2008 £284.8 m £32.5 m £88.4 m £32.5 m £569.0 m £13.5 m –£0.4 m £67.3 m £66.1 m £1153.6 m
2009 £337.9 m £39.1 m £103.5 m £32.0 m £578.6 m £14.5 m –£0.4 m £91.2 m £79.5 m £1276.0 m
2010 £390.5 m £45.4 m £120.7 m £34.5 m £644.3 m £16.3 m –£0.4 m £112.0 m £97.8 m £1461.2 m
2011 £540.9 m £62.5 m £166.3 m £38.9 m £697.3 m £12.6 m –£0.2 m £137.4 m £101.8 m £1757.4 m
2012 £605.4 m £70.3 m £187.4 m £40.8 m £712.0 m £9.3 m £0.0 m £134.8 m £106.9 m £1867.0 m
2013 £576.3 m £66.5 m £176.8 m £46.3 m £746.4 m £9.6 m –£0.2 m £132.0 m £106.1 m £1859.8 m
Total £4559.9 m £505.3 m £1395.4 m £565.2 m £6996.8 m £134.4 m –£5.3 m £1074.6 m £797.6 m £16,023.8 m
Fig. 4 Annual monetised QALYs, net costs of delivery and net monetary benefit – Musculoskeletal disease interventions 1994–2013
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Estimating the proportion of health gains that can be
attributed to United Kingdom research
The estimate of the proportion of the health gain that
can be attributed to United Kingdom research was also
based primarily on the analysis of cited references on
clinical guidelines. A total of 2762 publications were
analysed. The overall percentage across all guidelines,
using full counting6 as for the previous studies, was 30%,
which forms our central estimate, but as shown in
Table 5, this differed substantially between specific
guidelines. We also produced overall estimates using
fractional counting7 and the reprint address,8 which gave
an attribution to the United Kingdom of 25% and 24%,
respectively.
To produce a range of values for the sensitivity
analysis, we can consider the potential sources of
uncertainty in these estimates. We identify two likely
sources of error.
Firstly, we assume, for the purposes of our analysis, that
the proportion of research conducted in the United
Kingdom corresponds to the proportion supported by
United Kingdom (charitable or public) funding. However,
United Kingdom authors may receive funding from the
United Kingdom or overseas industry or from other non-
United Kingdom sources (notably the European Commis-
sion, but also other international funders). Equally, United
Kingdom funders may fund researchers overseas, but we
expect this to be limited in this field, and in most cases
this is likely to be in collaboration with at least one United
Kingdom author, in which case the full counting model
would capture the resulting publications. For the purposes
of our model, we assume flows of funding into and out of
the United Kingdom to be equal. Considering industry
funding, it may be that some of the papers with a United
Kingdom address are industry funded (including non-
United Kingdom industry), and as such should be ex-
cluded from the number of United Kingdom papers for
our estimate of attribution to the United Kingdom. We
expect this proportion to be small, but this is clearly an
issue which warrants further investigation.
Secondly, there is uncertainty around the relative
contribution of funding associated with each author
(and hence country) listed on each paper. The three
bibliometric methods all estimate this differently. Using
full counting effectively assumes that the United
Kingdom contributes all the funding for any paper
which has a United Kingdom author (and does the same
for any other countries on the same paper). This is likely
to overestimate the United Kingdom contribution.
Fractional counting at the author level assumes an equal
contribution of funding from each author on a paper
(from the country in which they are based). With reprint
addresses, the assumption is that all funding comes from
the country in which the corresponding author is based.
For the last two approaches, it is not clear whether they
are likely to give an under- or overestimation of the
proportion of funding from the United Kingdom. For
consistency with previous studies, we have used the full
counting approach for our central estimate.
Based on this analysis, we conclude that it is unlikely
that the United Kingdom contribution is higher than
our estimate from full counting of 30% (as used in
Fig. 5 Elapsed time of the cited papers extracted from guidelines
Glover et al. Health Research Policy and Systems  (2018) 16:1 Page 15 of 24
previous studies). However, it may be lower than our
lowest estimate using the reprint addresses of 24%,
considering the other potential sources of funding
available to United Kingdom-based researchers. Taking
this into account, we used lower and upper bounds of
20% and 30% for the sensitivity analysis.
Estimating the IRR from musculoskeletal disease research
Our estimates of the NMB produced by year
(summarised in Table 4) at a base-case value of a QALY
of £25,000 were then related to our best estimates of
public and charitable spend by year on MSD research
(summarised in Fig. 3) and expressed as an IRR. Calcula-
tion of the IRR incorporates our best estimates of the
average elapsed time between research spending and use
of the intervention (16 years) and of the proportion of
the NMB that could be attributable to United Kingdom
research (30%). This gives a base-case estimate of an IRR
of 6.8%.
As is evident from the methods used, there is
inevitably considerable uncertainty around the values of
all our estimates. Table 6 presents a series of one-way
Table 5 Proportion of publications from the United Kingdom for all guidelines included in the analysis
Guideline United Kingdom
papers
Total
papers
% United
Kingdom
British Association/College of Occupational Therapists – Hand and wrist orthoses for adults
with rheumatological conditions: practice guideline for occupational therapists (evidence)
5 25 20%
British Association/College of Occupational Therapists – Hand and wrist orthoses for adults
with rheumatological conditions: practice guideline for occupational therapists (supplementary)
10 20 50%
British Association/College of Occupational Therapists – Occupational therapy for adults
undergoing total hip replacement: practice guideline for occupational therapists (evidence)
9 30 30%
British Association/College of Occupational Therapists – Occupational therapy for adults
undergoing total hip replacement: practice guideline for occupational therapists (supplementary)
1 4 25%
British Pain Society – The assessment of pain in older people 6 63 10%
British Pain Society – Guidelines for pain management programmes for adults 21 55 38%
British Society for Rheumatology – British Society for Rheumatology and IASP Musculoskeletal
Pain Taskforce guidelines for the integrated management of musculoskeletal pain symptoms
(IMMsPS)
87 304 29%
British Society for Rheumatology – BSR guidelines on standards of care for persons with
rheumatoid arthritis
1 1 100%
National Institute for Health and Care Excellence – Hip fracture (CG.124) 73 254 29%
National Institute for Health and Care Excellence – Osteoporosis (CG.146) 32 71 45%
National Institute for Health and Care Excellence – Osteoarthritis (CG.177) 102 416 25%
National Institute for Health and Care Excellence – Rheumatoid arthritis in adults (CG.79) 102 337 30%
National Institute for Health and Care Excellence – Low back pain in adults (CG.88) 31 111 28%
National Osteoporosis Foundation – Clinician’s guide to the prevention and treatment
of osteoporosis
33 90 37%
National Osteoporosis Guideline Group – Guideline for the diagnosis and management
of osteoporosis in postmenopausal women and men from the age of 50 years in the
United Kingdom
2 2 100%
National Osteoporosis Guideline Group – Osteoporosis: clinical guideline for prevention
and treatment: executive summary
22 36 61%
National Osteoporosis Society – Vitamin D and bone health: a practical clinical guideline
for patient management
25 66 38%
Royal College of Nursing – Administering subcutaneous methotrexate for inflammatory arthritis 14 56 25%
Royal College of Physicians – Pain: complex regional pain syndrome 31 96 32%
Royal College of Physicians – Upper limb disorders: occupational aspects of management 2009 13 52 25%
Scottish Intercollegiate Guidelines Network – Management of hip fracture in older people (CG.111) 41 102 40%
Scottish Intercollegiate Guidelines Network – Management of early rheumatoid arthritis (CG.123) 23 83 28%
Scottish Intercollegiate Guidelines Network – Management of chronic pain (CG.136) 56 171 33%
Scottish Intercollegiate Guidelines Network – Management of osteoporosis and the prevention
of fragility fractures (CG.142)
92 317 29%
TOTAL 832 2762 30%
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sensitivity analyses to illustrate the effects of some of the
main areas of uncertainty – all changes have predictable
effects. Despite the detail of our estimation process there
is considerable uncertainty in the NMB; we present the
implications for the IRR of an arbitrary but plausible
range of −25% and +25% around our estimate to reflect
this. We also present the IRR omitting the cost-savings
from reduction in length of stay for hip and knee re-
placements (see Discussion). The impact of taking into
account the royalty payments arising from anti-TNF
research increased the IRR by 0.2 percentage points tak-
ing our lower figures (possible underestimate) and by 0.4
percentage points using our higher figures (likely
overestimate).
The IRR predictably decreases with increased estimates
of research funding and elapsed time and, as far as is
explored, all the variables in the one-way sensitivity ana-
lyses show a positive rate of return. However, in combin-
ation, they could of course have produced a wider range
of estimates for the IRR. Table 6 shows that, inevitably,
the IRR is most sensitive to the range of plausible values
that can be placed on the value of a QALY. At an oppor-
tunity cost in the NHS of £13,000, the IRR falls to 0.80%,
whilst at a societal valuation of £60,000 the IRR is 12.9%.
Discussion
In this paper, we have estimated the economic returns
from public and charitable funding of MSD-related
research in the United Kingdom. Expressed in 2013
prices, total expenditure on MSD-related research was
£1.4 billion for the period (1978–1997) that was used to
estimate the rate of return. Over the period 1994–2013,
the key interventions we analysed produced 871,000
QALYs with a NMB of £16 billion, allowing for the net
NHS costs resulting from them and valuing a QALY at
£25,000. The proportion of benefit attributable to United
Kingdom research was 30% and the elapsed time be-
tween funding and impact of MSD treatments was
16 years. Our best estimate of the IRR from MSD-
related research was 7%, very similar to the 9% for CVD
research and 10% for cancer research (Table 7). When
combined with previous estimates of the broader
Table 6 Internal rate of return: one way sensitivity analyses
IRR
Best Estimate 6.8%
Low research spend (£12 m) 7.6%
High research spend (£16 m) 6.0%
Omit length of stay reduction 5.5%
QALY £13 k 0.8%
QALY £20 k 5.0%
QALY £30 k 8.1%
QALY £60 k 12.9%
Long lag (20 years) 5.5%
Short lag (11 years) 8.1%
Low attribution to United Kingdom (20%) 4.5%
NMB −25% 5.1%
NMB +25% 8.0%
Royalty payments to public/charitable funders 7.0%
Total royalty payments 7.2%
IRR internal rate of return, QALY quality adjusted life years, NMB net
monetary benefit
Table 7 Comparison of key results with previous studies
MSD Cancer CVD
Average annual research investment
(for years of data used in IRR calculation as reported in source
publications, using different time period for calculating constant
prices and therefore not suitable for comparisons)
£70 m
(1978–1997, in constant
2013–2014 prices)
£266 m
(1976–1995, in constant
2011–2012 prices)
£111 m
(1975–1998, in constant
2005–2006 prices)
Average annual research investment
(rebased in same constant prices for comparative purposes)
£70 m
(1978–1997, in constant
2013–2014 prices)
£290 m
(1976–1995, in constant
2013–2014 prices)
£133 m
(1975–1998, in constant
2013–2014 prices)
Elapsed time
(between spending on research and health gain)
16 years 15 years 17 years
Attribution
(proportion of papers that include a United Kingdom address from
the papers cited on guidelines)
30% 17% 17%
Average NMB
(for years of data used in IRR calculation as reported in source
publications, but using different time period for calculating
constant prices therefore not suitable for comparisons)
£801 m
(1994–2013, in constant
2013–2014 prices)
£6223 m
(1991–2010, in constant
2011–2012 prices)
£2949 m
(1992–2005, in constant
2005–2006 prices)
Average NMB
(rebased in same constant prices for comparative purposes)
£801 m
(1994–2013, in constant
2013–2014 prices)
£6458 m
(1991–2010, in constant
2013–2014 prices)
£3559 m
(1992–2005, in constant
2013–2014 prices)
IRR (health gain) 7% 10% 9%
CVD cardiovascular disease, IRR internal rate of return, MSDmusculoskeletal disease, NMB net monetary benefit
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economic (or ‘spillover’) benefits of biomedical and
health research in the United Kingdom of 17% [4], the
total rate of return is approximately 24–27%.
In this study, we have also further tested the bottom-
up methodological approach developed in the original
‘Medical Research: What’s it worth?’ study [2]. The appli-
cation of this method to a further disease area that is dif-
ferent to CVD and cancer – particularly in terms of the
chronic nature of MSD and the predominantly quality of
life gains of the benefit of the interventions – confirms
the generalisability of our approach to estimate the eco-
nomic returns from research; that is not to say that it is
without limitations. We have organised the discussion
on limitations and caveats by first looking at the key
conceptual issues with the methodological approach,
followed by issues related to data availability and quality,
then an examination of a set of issues related to MSD
research, and, finally, a set of key caveats on what this
work demonstrates and what it does not.
Key conceptual assumptions inherent to methodological
approach
In estimating the economic returns from MSD-related
research (and indeed in the previous studies looking at
CVD and cancer research) various key assumptions are
made that are intrinsic to the conceptual approach
adopted:
 The total NMB for the interventions not covered
is assumed to be zero. Our estimate assumes that
any other MSD interventions introduced or widely
adopted during the period in question not included
in the analysis have, in aggregate, no effect on the
NMB, that is, their NMB is equivalent to zero. Put
another way we assume that, for any omitted
interventions, the monetised value of the health
benefit is equal to the cost of delivering the benefit.
This seems a reasonable assumption as there may be
interventions where the cost of delivery outweighs
the value of the benefit and others where the value
of the benefit outweighs the costs of delivery.
Without analysing all these other interventions, it
would be wrong to speculate on the balance of these
effects and therefore they are assumed to cancel
each other out. However, as discussed below, the
likelihood of this assumption being correct will vary
as the value of the QALY is decreased or increased
in the sensitivity analysis.
 The total net flow of knowledge between
disciplines is assumed to be zero.We know that
the relationship between research discipline and
impact is ‘many-to-many’ [61], that is research from
a specific discipline will contribute to multiple types
of impact and a specific impact is often made up of
contributions from multiple research disciplines. In
the context of the current study, it is likely, for
example, that MSD-related research benefits from,
say, cancer research and vice versa. We therefore as-
sume that the flow of knowledge is the same in to as
it is out of different research fields, in effect cancel-
ling each other out.
 The definition of MSD-related research used by
the research funders captures basic research.We
know this is the case for ARUK and the other
disease-specific medical research charities as all their
research funding is included in the analysis. For the
FCs and the DH/NHS this would not be an issue as
estimates for their MSD-related research funding
were derived by applying the ‘activity index’, which
would include basic research. However, for the MRC
and WT this could be an issue. For the MRC, we re-
lied on the funder’s classification and used the
broader of two definitions so that we would deliber-
ately err on the side of caution by taking the higher
level of R&D spend. For the WT, we had to rely on
search terms and in scanning research grant titles
we were reassured that fundamental research was
included.
 The cost of private sector R&D is covered in the
net NHS costs of the interventions.We assume
that the costs of private sector R&D (i.e. non-
public and non-charitable research expenditure)
are accounted for when we net off the NHS costs
for an intervention. This assumption holds for
purely commercial research as, say, a pharmaceut-
ical company will include the cost of their R&D
investments in the price of a drug. It may be that
companies invest in ‘non-commercial’ activities,
such as public–private partnerships or precompe-
titive consortia, and in effect are subsidising the
public sector research in doing so. However, even
in this case (which is probably at the margins of
total R&D investments) it is unlikely that the pri-
vate sector is doing so in isolation of commercial
considerations and it will recoup such costs
through its sales revenues.
 All health gains arise from specific patient
interventions.We assume that all health gains
arise from, and are captured in, our estimates of
the health gain from specific patient interventions.
We recognise that broader service changes, such
as the adoption of fracture clinics, or
improvements in diagnosis are important but
assume that they lead to patients receiving timely
and appropriate interventions for which we
estimate the QALYs gained. There is a possibility
that we are failing to net off the full costs of
such developments in service delivery if the cost-
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effectiveness evidence we use for such interven-
tions fails to reflect the full cost of the service de-
livery associated with them.
 We have assumed there is a causal relationship
between research and health gains. Our analysis
relies on the assumption that the health benefits
would not have occurred without the evidence from
the medical research. Our bottom-up approach has
the advantage that, for the individual interventions,
there is causality as demonstrated through their for-
mal clinical trials. Additionally, in this disease area
we do not have the uncertainty as to any causal fac-
tors, other than medical research, that may have led
in part to a reduction in smoking. Furthermore, in
previous research on MSD, we used a case study ap-
proach that clearly demonstrated causality for the
small number of interventions examined [62, 63].
Uncertainties relating to key parameters
There remain a number of uncertainties with the
bottom-up approach that relate to the nature, quality
and availability of data that are relevant to this examin-
ation of MSD research, and were also the case for CVD
and cancer research. Reducing the uncertainty with
these data issues would improve the robustness of the
IRR estimate and thus, in part, could inform future re-
search avenues.
 The monetary value of a QALY. As noted earlier
in the paper, there is ongoing debate as to the
appropriate value of a QALY. Our base-case assump-
tion of £25,000 is consistent with our analysis of the
returns to CVD and cancer research, and reflects the
mid-point in the range of values (of £20,000 to
£30,000) cited as normal criteria for acceptance of
interventions by NICE [24]. However, as highlighted
above, if the QALY is valued either at a lower (e.g.
£13,000) or higher (e.g. £60,000) level then this could
affect our core assumption that the total NMB for any
new interventions not covered is assumed to be zero.
If QALYs are valued at £60,000 then more interven-
tions are likely to have a positive NMB among those
not looked at, meaning that we are underestimating
the rate of return. Conversely, if the QALY is valued
at £13,000, then more interventions in those not
looked at are likely to have a negative NMB, meaning
that we are over estimating the rate of return.
 Estimates of the elapsed time are hard to
determine. As with the previous studies,
bibliometric analysis of clinical guidelines was used
to estimate the time between research investment
and health gain. The advantage of this approach is
that it provides empirical estimates, but it is also,
inevitably, a gross simplification of a complex and
varied process, as we have discussed elsewhere
[64, 65]. The estimate of the elapsed time is in
accordance with other estimates using different
approaches as reviewed by Morris et al. [66], but
is still a crude proxy and is an area that would
benefit from further research.
 Estimates for the rate of attribution are very
hard to determine. Like the estimate of the elapsed
time, bibliometric analysis of clinical guidelines was
used to estimate the proportion of the United
Kingdom health gains that can be related to United
Kingdom public and charitable research funding.
However, the estimate of the attribution rate is
harder to validate than the elapsed time and is thus
more contestable. It is also becoming increasingly
difficult to define, given the steady increase in
international collaboration in research observed in
recent decades [67]. Identifying any one country’s
contribution without a qualitative assessment of the
research itself can only provide an uncertain
estimate, but one that we believe is likely to be more
robust at the aggregate level of an entire research
field. Biases in coverage of bibliometric databases,
particularly as regards languages other than English,
should also be noted. An attribution rate of at least
7–9% would be expected given that the United
Kingdom contributes approximately 7–9% of
biomedical and health research outputs [68]. One
could also argue that the rate would be somewhat
higher than this given that the local healthcare
context is likely to drive the need for locally relevant
studies. In the previous two studies, the attribution
rate was 17% for both CVD and cancer (Table 7),
which, given the above logic, felt defensible.
However, an attribution rate of 30% for MSD seems
high and was at the top end of the estimates we
generated using different bibliometric methods.
Thus, and although we used 30% for consistency
with the previous studies, we did not include a
higher upper bound estimate in the sensitivity
analysis. It may also be that a proportion of papers
cited on the clinical guidelines are solely private
sector-funded and thus overstate the attribution rate
to publically funded research (a scan of the refer-
ences suggests that approximately 10% of United
Kingdom papers could be solely industry funded).
Either way a clear priority for future research would
be to further examine how you measure how much
of the United Kingdom health gain you can attribute
to United Kingdom public and charitable research,
and to validate or otherwise the guideline
methodology.
 Missing funding data. Historical data on research
funding expenditure was incomplete, meaning that
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we had to make a number of assumptions to
account for missing data. These assumptions erred
on the side of caution and were tested in the
sensitivity analysis of the IRR. As we have previously
noted [2], if research funders wish to carry on with
this type of analysis, the continued use of standard
systems of research classification such as the HRCS
will be important.
Key issues particular to MSD
There are a number of specific issues that relate to the
assessment of MSD research, as indicated below.
 Quality of data.We had expected that there might
be greater problems in identifying cost-effectiveness
data in MSD given that the outcomes of interven-
tions are principally improvements in quality of life.
In practice, there was relatively good data on the
cost-effectiveness and usage of new drugs, reflecting
that many had been subject to NICE appraisals. By
contrast, there was much less cost-effectiveness data
and very poor data on provision and usage for some
interventions such as those for back pain. In part,
this reflects the complexity and variability of the
physical therapies potentially provided to multiple
groups of MSD patients. There are issues about the
generalisability of clinical trials and associated cost-
effectiveness studies and an absence of consistent
routine methods of data collection on their usage.
 Pricing of new pharmacological interventions.
One of the major therapeutic developments in the
period was the advent of biologic DMARDs
including anti-TNFs. Our analysis shows that these
made a substantial contribution to the QALYs
gained, but as most were priced to try to meet
NICE’s cost-effectiveness ‘threshold’ they contrib-
uted rather little to our estimates of NMB. However,
as biosimilars now become available these drugs will,
in future, if not superseded by other new interven-
tions, contribute more strongly to any estimate of
NMB. By contrast, early aggressive treatment with
generic methotrexate provides both QALYs and a
high NMB.
 Importance of reductions in length of stay. Our
clinical experts emphasised the importance of
changes in practice during the relevant period that
had reduced lengths of stay and hence costs for
some key procedures. They noted that, whilst desire
for the reduction may have been driven by cost
considerations, the change in practice was supported
by research evidence showing no reduction in health
benefit [69–71]. Review of the data showed that the
change was marked and we estimated the cost
savings in the case of hip and knee replacements.
However, we are aware that there may have been
some similarly marked changes that we did not
quantify in previous studies. Whilst we do not
believe they would have been so significant in the
case of CVD or cancer we provide a sensitivity
analysis to show the IRR for MSD if these cost
savings are excluded.
 Other interventions that we might have
included. Some advances in the treatment of
musculoskeletal connective tissue disorders have
occurred over the period of interest, but data on
their cost-effectiveness is limited. For example, there
was a lack of cost-effectiveness data for other im-
munosuppressant therapies in SLE and scleroderma,
notably cyclophosphamide and intravenous im-
munoglobulin for the treatment of dermatomyositis.
The net health gains associated with rituximab use
in SLE were also not quantified in the model due to
a lack of data. Similarly, we were unable to charac-
terise the cost-effectiveness and to find appropriate
data on specific treatments for soft-tissue musculo-
skeletal pain (M60–M79). As noted above, for any
area we were not able to analyse specifically, our
methods implicitly assume that any benefits from
treatment were directly offset by their costs of deliv-
ery (i.e. the NMB is 0). However, we are confident
that our analysis directly captures most of the sig-
nificant advances in the field that have produced im-
portant health or cost effects when viewed at a
population level, and unlike our analysis of cancer,
because the MSD field is smaller, we did not have to
prioritise and effectively ignore some potentially im-
portant areas.
 The treatment of royalty payments. The
particular circumstances of the commercialisation of
anti-TNF research led us to consider for the first
time in this study the impact on the IRR of the sig-
nificant royalty payments, although we were unable
to establish the precise total magnitude of the roy-
alty payments that were returned to publicly funded
medical research. The impact was not negligible
although they did not significantly change the order
of magnitude of the IRR. We are not aware of royal-
ties of a similar relative magnitude in the case of our
previous studies on CVD and cancer, but clearly it is
an issue that needs to be considered and refined in
future studies.
Key limitations and caveats to the ‘bottom-up’ approach
for assessing economic returns
There are three key caveats that are fundamental to
appropriately using the results presented in this and the
previous papers in assessing the economic rates of
return for MSD, cancer and CVD research.
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 We have assessed past performance, not
predicted future performance. In all three studies,
we have estimated the rate of return based on
past investments and therefore our results
cannot be a guarantee of future returns –
medical research does not advance in a smooth
and linear fashion. This is a crucial caveat when
using these results to advocate the need for
future research spending.
 We have assessed the average rate of return, not
the marginal rate of return. From the analysis, we
are not able to say whether the rate of return would
have been different if research spending had been
higher or lower, or whether at the margin the
returns to research investment are increasing or
decreasing. Assessing the marginal rate of return is
of clear interest to policy-makers and this is a topic
that warrants further research attention.
 Our estimates should not be used to make
comparisons between disease area or
intervention. Given the inherent assumptions and
uncertainty in our approach we strongly counsel
against making comparisons between the three
disease areas we have examined or specific
interventions within those disease areas. Taking the
three studies together, we believe it is appropriate to
say the IRR arising from health gains to the United
Kingdom, from United Kingdom research, is
between 7% and 10%.
It is of course impossible to know whether our
estimates of the return are accurate in the absence of
an observation of a control to provide the
counterfactual. The likely validity of our estimates can
only be judged through the reasonableness of the
many assumptions about which we have tried to be
entirely transparent. Should readers have more or less
confidence in them because of the similarity between
the estimates for IRR arising from health gains across
the three studies? The results are indeed remarkably
comparable (Table 7). This can either be interpreted
positively as some form of internal validation of
plausible magnitudes, or negatively to suggest that
something inherent in the methodology leads to this
similar outcome. We are not aware of any aspect of
our methods that suggests this is a methodological
artefact. Rather, we draw some comfort from the fact
that the similarity arises despite the inputs (research
expenditure) and outcomes (NMB) being very
different between the studies and for separate groups
of interventions within each of them. The fact that
the elapsed times are similar has a degree of face
validity, as does the relatively high level of attribution
for MSD, which, as already noted, given its chronic
nature, is more likely to be influenced by local
contextual research.
Conclusion
The public, both as taxpayers and charity donors, invest
a significant amount of money into biomedical and
health research each year. Understanding the economic
impact of this investment provides accountability, helps
secure future research investments and increases our
understanding of how research is effectively translated
into health improvements. In a series of studies looking
at the net value of improved health outcomes, in CVD,
cancer and MSD we have demonstrated an IRR of
between 7% and 10%. When we include the 17% return
for the broader economic or ‘spillover’ impact this rises
to between 24% and 27%. The results suggest that,
despite the uncertainties around the methods and
estimates, the historical returns in terms of NMB of the
health gains derived in the United Kingdom from public
and charitably funded biomedical and health research
are substantial and justify the investments made.
Endnotes
1The Health Research Classification System (HRCS) is
a two-dimensional framework. Codes from both HRCS
dimensions are applied when classifying; one dimension,
the Health Categories, is used to classify the type of
health or disease being studied. There are 21 categories
encompassing all diseases, conditions and areas of health.
The other dimension, the Research Activity Codes, classi-
fies the type of research activity being undertaken (from
basic to applied). There are 48 codes divided into eight
groups. See http://www.hrcsonline.net/rac/rac for more
details. The data cited are on DALY rates from 2012 and
research spend data from 2014.
2Figures given between 1992 and 1993 show the UFC
grants after the funds were transferred from the UFC to
the Research Councils.
3Prepared by the HEFCE Analytical Services Group on
13 February 2008. Figures for 1993–1994 to 1996–1997
were adjusted to include an estimate of funds for
research capital that were rolled into mainstream
quality-related research (QR) from 1997–1998 onwards.
No adjustments have been made to counterbalance the
effect of the phased transfer of funds to the United King-
dom Research Councils in 1992–1993, 1993–1994 and
1994–1995. Figures for Units of Assessment (UoA) 12:
Biochemistry, which ceased to exist in the 2001 Research
Assessment Exercise, have been rolled into UoA 14:
Biological Sciences. Figures exclude funds for the super-
vision of students on research degree programmes,
London weighting, and all other relatively minor ele-
ments of research funding. For 2006–2007, 2007–2008
and 2008–2009, the QR charity support element has
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been added to mainstream QR funds to reflect the
change in the way research income from charities is
used in the calculation of funding. Figures contain rela-
tively minor grant adjustments made to the database
after the initial grant allocations announced in March
each year.
4Figures for 2010–2011 do not reflect the 1.7%
retrospective reduction announced in HEFCE Circular
Letter 05/11 and applied at institution level. In the
calculations that include quality-related research (QR) char-
ity support funding (below), the proportion of QR charities
support funding attributed to biomedical Units of Assess-
ment in 2011–2012 has been applied to 2012–2013.
5The Centre for Science and Technology Studies
(CWTS) maintains a bibliometric database of all
scientific publications (including health and biomedical
research) for the period 1981 to 2016. This dataset is
based on the journals and serials processed for the Core
Collection version of the Web of Science database,
including the Science Citation Index Expanded (SCI-E)
and associated citation indices, the Social Sciences Citation
Index (SSCI), and the Arts & Humanities Citation Index
(A&HCI). This database is operated for bibliometric
purposes in service contracts under a License Agreement
with Clarivate Analytics. See: https://www.cwts.nl/ for
more information.
6Full counting is an approach in which a paper which
has authors from multiple countries will be attributed in
full to each of these countries. Therefore, the estimate of
30% indicates that the United Kingdom contributed to
30% of the papers analysed. However, there will be
contributors from other countries to many of these
papers. This approach is used for the central estimate as
it was used in the previous studies, to aid comparison.
7In fractional counting, attribution of a paper is shared
between the countries of origin of the various authors.
For example, if a paper has one author from the United
Kingdom and two from the United States, the United
Kingdom will receive attribution for one third of a
paper, and the other two thirds will go to the United
States.
8This is an alternative approach where papers are
attributed to the country of origin of the corresponding
author. The logic is that it is likely that the institution of
the corresponding author held a significant proportion
of the funding for the work and made a significant
contribution to the work.
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